After a slow couple of years, there are signs that biotech M&A activity is coming back into vogue, and a series of small transactions announced in the last few days pr
Five years AstraZeneca became an oncology trailblazer by getting the first PARP inhibitor class drug Lynparza, approved by the FDA for certain ovarian cancers.